In vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane‐caffeine, potassium chloride, suxamethonium and caffeine‐suxamethonium

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

In vitro diagnosis of susceptibility to malignant hyperthermia : evaluation of tests with halothane‐caffeine, potassium chloride, suxamethonium and caffeine‐suxamethonium. / ØRding, H.; Skovgaard, L. T.

In: Acta Anaesthesiologica Scandinavica Supplementum, Vol. 31, No. 5, 07.1987, p. 462-465.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

ØRding, H & Skovgaard, LT 1987, 'In vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane‐caffeine, potassium chloride, suxamethonium and caffeine‐suxamethonium', Acta Anaesthesiologica Scandinavica Supplementum, vol. 31, no. 5, pp. 462-465. https://doi.org/10.1111/j.1399-6576.1987.tb02604.x

APA

ØRding, H., & Skovgaard, L. T. (1987). In vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane‐caffeine, potassium chloride, suxamethonium and caffeine‐suxamethonium. Acta Anaesthesiologica Scandinavica Supplementum, 31(5), 462-465. https://doi.org/10.1111/j.1399-6576.1987.tb02604.x

Vancouver

ØRding H, Skovgaard LT. In vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane‐caffeine, potassium chloride, suxamethonium and caffeine‐suxamethonium. Acta Anaesthesiologica Scandinavica Supplementum. 1987 Jul;31(5):462-465. https://doi.org/10.1111/j.1399-6576.1987.tb02604.x

Author

ØRding, H. ; Skovgaard, L. T. / In vitro diagnosis of susceptibility to malignant hyperthermia : evaluation of tests with halothane‐caffeine, potassium chloride, suxamethonium and caffeine‐suxamethonium. In: Acta Anaesthesiologica Scandinavica Supplementum. 1987 ; Vol. 31, No. 5. pp. 462-465.

Bibtex

@article{711c5def74c8438aa7c2b4ecd7bbf425,
title = "In vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane‐caffeine, potassium chloride, suxamethonium and caffeine‐suxamethonium",
abstract = "Susceptibility to MH was determined in 77 patients according to the protocol of the European MH Group. Additional muscle bundles were used for diagnostic in vitro tests with caffeine in the presence of 1 % halothane, potassium chloride, suxamethonium, and caffeine‐suxamethonium. Significant differences between MH‐susceptible (MH) and MH‐negative (MHN) patients were obtained with the halothane‐caffeine test and the potassium chloride test, whereas no differences were found with the suxamethonium test. In the test with caffeine‐suxamethonium, a different response to caffeine but not to suxamethonium was obtained. In all tests there was an overlap in results between MHS and MHN groups, and the predictive values of the tests ranged between 63 and 95%. Prior small doses of caffeine followed by a 4 mmol/l dose of caffeine elicited significantly smaller contractures than 4 mmol/l given as the first dose of caffeine. This underlines the necessity of a common protocol for performance and interpretation of diagnostic tests for MH.",
keywords = "Anesthetics, caffeine, halothane, malignant hyperthermia, potassium chloride, suxamethonium",
author = "H. {\O}Rding and Skovgaard, {L. T.}",
year = "1987",
month = jul,
doi = "10.1111/j.1399-6576.1987.tb02604.x",
language = "English",
volume = "31",
pages = "462--465",
journal = "Acta Anaesthesiologica Scandinavica",
issn = "0001-5172",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - In vitro diagnosis of susceptibility to malignant hyperthermia

T2 - evaluation of tests with halothane‐caffeine, potassium chloride, suxamethonium and caffeine‐suxamethonium

AU - ØRding, H.

AU - Skovgaard, L. T.

PY - 1987/7

Y1 - 1987/7

N2 - Susceptibility to MH was determined in 77 patients according to the protocol of the European MH Group. Additional muscle bundles were used for diagnostic in vitro tests with caffeine in the presence of 1 % halothane, potassium chloride, suxamethonium, and caffeine‐suxamethonium. Significant differences between MH‐susceptible (MH) and MH‐negative (MHN) patients were obtained with the halothane‐caffeine test and the potassium chloride test, whereas no differences were found with the suxamethonium test. In the test with caffeine‐suxamethonium, a different response to caffeine but not to suxamethonium was obtained. In all tests there was an overlap in results between MHS and MHN groups, and the predictive values of the tests ranged between 63 and 95%. Prior small doses of caffeine followed by a 4 mmol/l dose of caffeine elicited significantly smaller contractures than 4 mmol/l given as the first dose of caffeine. This underlines the necessity of a common protocol for performance and interpretation of diagnostic tests for MH.

AB - Susceptibility to MH was determined in 77 patients according to the protocol of the European MH Group. Additional muscle bundles were used for diagnostic in vitro tests with caffeine in the presence of 1 % halothane, potassium chloride, suxamethonium, and caffeine‐suxamethonium. Significant differences between MH‐susceptible (MH) and MH‐negative (MHN) patients were obtained with the halothane‐caffeine test and the potassium chloride test, whereas no differences were found with the suxamethonium test. In the test with caffeine‐suxamethonium, a different response to caffeine but not to suxamethonium was obtained. In all tests there was an overlap in results between MHS and MHN groups, and the predictive values of the tests ranged between 63 and 95%. Prior small doses of caffeine followed by a 4 mmol/l dose of caffeine elicited significantly smaller contractures than 4 mmol/l given as the first dose of caffeine. This underlines the necessity of a common protocol for performance and interpretation of diagnostic tests for MH.

KW - Anesthetics

KW - caffeine

KW - halothane

KW - malignant hyperthermia

KW - potassium chloride

KW - suxamethonium

UR - http://www.scopus.com/inward/record.url?scp=0023255505&partnerID=8YFLogxK

U2 - 10.1111/j.1399-6576.1987.tb02604.x

DO - 10.1111/j.1399-6576.1987.tb02604.x

M3 - Journal article

C2 - 3630591

AN - SCOPUS:0023255505

VL - 31

SP - 462

EP - 465

JO - Acta Anaesthesiologica Scandinavica

JF - Acta Anaesthesiologica Scandinavica

SN - 0001-5172

IS - 5

ER -

ID: 259166678